Several studies have attempted to engineer CAR-T, NK, and M cells targeting specific antigens in hepatocellular carcinoma, such as glypican-3 (GPC3), showing promising initial results; however, further improvements and optimizations are necessary (30, 151, 161). This evidence concerns the gene GPC3 and hepatocellular carcinoma.